- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07736105
Optimizing Dysphagia Treatment Delivery in Acute Care: A Hybrid Efficacy Implementation Trial
This research study is investigating the efficacy and implementation of expiratory muscle strength training (EMST), standard of care dysphagia treatment, and intensive dysphagia treatment in critically ill adults in the acute care setting. Currently, no targeted, effective, and feasible dysphagia treatment approaches currently exist for use in critically ill adults in the acute care setting. The current study will investigate the impact of EMST, standard of care dysphagia treatment, and intensive dysphagia treatment on pulmonary function, cough function, swallow function, frailty, patient-reported swallow function, and health outcomes in critically ill adults. This study will also examine patient perceptions and clinical speech-language pathologists' perceptions of the acceptability, appropriateness, and feasibility of these interventions.
Critically ill adults will: undergo tests of breathing, cough, and swallow function, complete questionnaires about the treatment, and their swallow function, and complete their respective treatment as prescribed.
Clinical speech-language pathologists will complete questionnaires about the interventions.
A subset of critically ill adults and clinical speech-language pathologists will also have the opportunity to participate in focus groups.
Study Overview
Status
Conditions
Detailed Description
This study will involve two in-person research evaluations in the hospital that will last 45 minutes- 1 hour and will consist of a screening, breathing and cough testing, swallow function testing, measures of frailty, and completion of questionnaires. Following the initial research evaluation, critically ill adults will complete the intervention they are assigned to as prescribed. The exercises will take 15-20 minutes to complete and adherence to treatment will be tracked. Prior to hospital discharge and after completion of the intervention, critically ill adults will undergo a second research evaluation.
Clinical speech-language pathologists will complete questionnaires about the interventions that will take 10-15 minutes.
A subset of critically ill adults and clinical speech-language pathologists will also have the opportunity to participate in focus groups, which will take 45 minutes-1 hour.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Cara Donohue, PhD CCC-SLP
- Phone Number: 615-852-5085
- Email: cara.donohue@vumc.org
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
Contact:
- Cara Donohue, PhD CCC-SLP
- Phone Number: 615-852-5085
- Email: cara.donohue@vumc.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion criteria for critically ill adults will be:
- Adult ≥ 18 years old
- Not pregnant
- Underwent a clinical flexible endoscopic evaluation of swallowing (FEES) or videofluoroscopy swallow study (VFSS) with a penetration aspiration scale (PAS) score ≥ 5
- Hospitalized in non-neuro intensive care unit (ICU) setting at Vanderbilt University Medical Center (VUMC) at some point during admission
- Dysphagia is primarily related to ICU stay and not other medical conditions that may cause dysphagia
- medically cleared with no contraindications for expiratory muscle strength training (EMST) or other treatments
- Cognitive capacity to follow basic directions
- Willing to undergo testing and treatment for the study.
Inclusion criteria for speech-language pathologists (SLPs) will be:
- Adult acute care speech-language pathologist who works at VUMC.
- Willing to complete surveys and/or participate in a focus group.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Expiratory muscle strength training (EMST)
Critically ill adults will complete EMST as prescribed.
|
EMST devices will be set to 60% of participants' maximum expiratory pressure.
Participants will complete training 5 days per week by performing 5 sets of 5 repetitions.
|
|
Active Comparator: Standard of Care Dysphagia Treatment
Critically ill adults will receive dysphagia treatment per standard of care.
|
Critically ill adults will perform one set of ten repetitions of each exercise recommended by their clinical speech-language pathologist.
Enrolled participants will complete up to two training sessions per week (0-2 pending normal clinical care course) with a clinical speech-language pathologist
|
|
Experimental: Intensive Dysphagia Treatment
Critically ill adults will complete intensive dysphagia treatment as prescribed.
|
Critically ill adults will perform one set of ten repetitions of each exercise (effortful swallow, Masako maneuver, Mendelsohn maneuver, chin tuck against resistance, tongue strengthening exercises, and may also participate in bolus driven therapy).
Enrolled participants will complete five training sessions per week (at least 3 days/week with the PI or a trained member of the research team and up to 2 days/week with a member of the clinical speech-language pathology team).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Dynamic Imaging Grade of Swallowing Toxicity Scale (DIGEST) Grades
Time Frame: pre-treatment (baseline), and post-treatment prior to hospital discharge, assessed up to 2 weeks
|
The DIGEST is a validated, 5-point ordinal rating scale that quantifies global pharyngeal swallow function.
|
pre-treatment (baseline), and post-treatment prior to hospital discharge, assessed up to 2 weeks
|
|
Change in Penetration Aspiration Scale Scores
Time Frame: pre-treatment (baseline), and post-treatment prior to hospital discharge, assessed up to 2 weeks
|
The penetration aspiration scale is a validated 8-point ordinal rating scale that measures the depth of airway invasion and the patient's response during swallowing.
Scores range from 1 to 8 with a score of 1 indicating a safe swallow (best score) and 8 indicating silent aspiration (worst score).
|
pre-treatment (baseline), and post-treatment prior to hospital discharge, assessed up to 2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in maximum expiratory pressure
Time Frame: pre-treatment (baseline), and post-treatment prior to hospital discharge, assessed up to 2 weeks
|
A measure of respiratory strength while breathing out
|
pre-treatment (baseline), and post-treatment prior to hospital discharge, assessed up to 2 weeks
|
|
Change in cough peak expiratory flow
Time Frame: pre-treatment (baseline), and post-treatment prior to hospital discharge, assessed up to 2 weeks
|
A measure of cough strength
|
pre-treatment (baseline), and post-treatment prior to hospital discharge, assessed up to 2 weeks
|
|
Grip strength
Time Frame: pre-treatment (baseline), and post-treatment prior to hospital discharge, assessed up to 2 weeks
|
Change in Grip strength be used to quantify clinical frailty using a digital hand dynamometer.
|
pre-treatment (baseline), and post-treatment prior to hospital discharge, assessed up to 2 weeks
|
|
Change in Swallowing and Eating Related Fatigue Questionnaire (SERF)
Time Frame: pre-treatment (baseline), and post-treatment prior to hospital discharge, assessed up to 2 weeks
|
Scores on the SERF range 0-48 with higher scores indicating greater impairment.
|
pre-treatment (baseline), and post-treatment prior to hospital discharge, assessed up to 2 weeks
|
|
Change in Screening for Oral Frailty Tool (SOFT)
Time Frame: pre-treatment (baseline), and post-treatment prior to hospital discharge, assessed up to 2 weeks
|
Oral frailty will be assessed as present/absent using the Screening for Oral Frailty Tool.
|
pre-treatment (baseline), and post-treatment prior to hospital discharge, assessed up to 2 weeks
|
|
Change in Eating Assessment Tool 10 (EAT-10)
Time Frame: pre-treatment (baseline), and post-treatment prior to hospital discharge, assessed up to 2 weeks
|
The EAT-10 contains 10 questions (score range: 0-40), higher scores indicate greater impairment.
|
pre-treatment (baseline), and post-treatment prior to hospital discharge, assessed up to 2 weeks
|
|
Acceptability of Intervention Measure (AIM)
Time Frame: post-treatment prior to hospital discharge, assessed up to 2 weeks
|
A measure of how acceptable an intervention is with scores ranging from 4-20.
|
post-treatment prior to hospital discharge, assessed up to 2 weeks
|
|
Intervention Appropriateness Measure (IAM)
Time Frame: post-treatment prior to hospital discharge, assessed up to 2 weeks
|
A measure of how appropriate an intervention is with scores ranging from 4-20.
|
post-treatment prior to hospital discharge, assessed up to 2 weeks
|
|
Feasibility of Intervention Measure (FIM)
Time Frame: post-treatment prior to hospital discharge, assessed up to 2 weeks
|
A measure of how feasible an intervention is with scores ranging from 4-20.
|
post-treatment prior to hospital discharge, assessed up to 2 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Cara Donohue, PhD CCC-SLP, Vanderbilt University Medical Center
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Disease Attributes
- Respiratory Tract Diseases
- Digestive System Diseases
- Gastrointestinal Diseases
- Respiration Disorders
- Esophageal Diseases
- Otorhinolaryngologic Diseases
- Signs and Symptoms, Respiratory
- Pharyngeal Diseases
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Critical Illness
- Respiratory Aspiration
- Deglutition Disorders
- Cough
Other Study ID Numbers
- 261042
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.